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Antibody-mediated rejection (AMR) is gaining increasing recognition as a major complication after heart transplantation, posing
asigniﬁcantriskforallograftfailure,cardiacallograftvasculopathy,andpoorsurvival.AMRresultsfromactivationofthehumoral
immune arm and the production of donor-speciﬁc antibodies (DSA) that bind to the cardiac allograft causing myocardial
injury predominantly through complement activation. The diagnosis of AMR has evolved from a clinical diagnosis involving
allograftdysfunctionandthepresenceofDSAtoaprimarilypathologicdiagnosisbasedonhistopathologyandimmunopathology.
Treatment for AMR is multifaceted, targeting inhibition of the humoral immune system at diﬀerent levels with emerging agents
including proteasome and complement inhibitors showing particular promise. While there have been signiﬁcant advances in our
current understanding of the pathogenesis, diagnosis, and treatment of AMR, further research is required to determine optimal
diagnostic tools, therapeutic agents, and timing of treatment.
1.Introduction
Antibody-mediated rejection (AMR) is a diagnostic and
therapeutic challenge in human heart transplantation.
Although the true incidence of AMR is unknown, it has
been reported in 10–20% of patients after heart transplant,
typically occurring within a few months after transplant [1,
2]. Late occurrences are, however, not uncommon with one
study reporting 25% of AMR cases occurring more than one
year after transplantation [1]. A diagnosis of AMR portends
a poorer prognosis with an increased incidence of allograft
dysfunction, mortality, and cardiac allograft vasculopathy
(CAV) [3].
AMR was ﬁrst described as a clinical entity in 1987 by
Herskowitz et al. who identiﬁed a subset of heart transplant
patients with arteriolar vasculitis and poor outcomes [4].
Hammond et al. subsequently showed that vascular rejection
was associated with antibody deposition and complement
activation [5]. In 2005, the International Society for Heart
and Lung Transplant (ISHLT) published speciﬁc guidelines
for the diagnosis of AMR [6]. An updated consensus was
released in 2011, including a separate companion document
detailing theworkingformulationforthepathologicdiagno-
sis of AMR [7, 8]. This paper will discuss the current under-
standing of AMR, focussing on pathogenesis, diagnosis, and
treatment.
2. Pathogenesis
AMR occurs due to a humoral immune response with anti-
bodies binding to endothelium on the transplanted heart
[5]. The antibodies are typically directed against human
leukocyte antigen (HLA) class I or class II molecules. Anti-
bodies reactive against donor HLA molecules are termed
donor-speciﬁc antibodies (DSA). These may be preformed
and present prior to transplantation or arise de novo after2 Journal of Transplantation
Table 1: Deﬁnition of allograft dysfunction (≥1 criteria required).
Clinical heart failure Symptoms and signs of low cardiac output and/or pulmonary or systemic congestion
Hemodynamics PCWP > 20mm Hg, and CI < 2.0L/min/m2
Inotropes Requirement for inotropic drugs
Restrictive physiology
Echocardiogram: LVEF >50%, E to A ratio >2, IVRT <60ms and DT <150ms
Or
Right heart catheterization: RAP >12mmHg, PCWP >25mmHg and CI < 2.0L/min/m2
Systolic dysfunction LVEF ≤45% or FS ≤20% or ≥25% decrease of LVEF or FS from baseline
A: A-wave, CI: cardiac index, DT: deceleration time, E: E-wave, FS: fractional shortening, IVRT: isovolumic relaxation time, LVEF: left ventriculare j e c t i o n
fraction, PCWP: pulmonary capillary wedge pressure, and RAP: right atrial pressure.
transplantation. The importance of non-donor-speciﬁc HLA
antibodies arising de novo after transplant is unclear, but
may be relevant as they potentially indicate an increased
risk for humoral activation. Risk factors for AMR include
recipient female sex, multiparity, prior blood transfusions,
retransplantation, positive perioperative T-cell ﬂow cytome-
try crossmatch, elevated panel-reactive antibodies, and prior
ventricular assist device [1, 3]. These factors, in common,
reﬂect enhanced humoral responses to antigens and the
development of DSA.
DSA binding to the allograft causes myocardial injury
and allograft dysfunction predominantly through immune
complex activation of the classical pathway of the comple-
ment cascade [9]. Antigen-antibody complexes bind to C1q,
and in a series of ampliﬁed steps, terminal complement
components form the membrane attack complex leading
to target cell lysis. Complement activation without cell
lysis can result in endothelial activation promoting further
inﬂammation [10]. Active complement fragments, C3a and
C5a exert direct eﬀects on endothelial cells and are also
chemotactic, recruiting neutrophils and macrophages [9,
11]. The split products C4d and C3d are formed during
complementactivationandcovalentlybindtoproteintargets
[12]. C4d and C3d have therefore been used as surrogate
markers of complement activation.
Anti-HLA antibody binding may also lead to endothelial
cell activation by complement independent mechanisms.
Direct cross-linking of HLA molecules on the cell surface
can activate endothelial cells and lead to the production
of growth factors such as ﬁbroblast growth factor, platelet-
derived growth factor, monocyte chemotactic protein as
well as cytokines and adhesion molecules [13, 14]. Immune
eﬀector cells such as natural killer cells, macrophages and
neutrophils may also bind to antibody-bound endothelial
cells via Fc receptors [12]. These immune eﬀector cells
further enhance the inﬂammatory milieu through cytotoxic
actions and via cytokine release. Thus, both complement
and noncomplement ﬁxing DSA may activate and injure
endothelial cells, thereby predisposing transplant recipients
with AMR to the development of CAV [15–17].
The role of non-HLA antibodies in AMR remains
an area of contention. Recently, Nath et al. showed that
non-HLA antibodies directed against cardiac myosin and
vimentin were elevated in heart transplant recipients who
subsequentlydevelopedAMRandCAV[18].Theappearance
of DSA preceded the appearance of non-HLA antibodies.
The authors concluded that both allo- and auto-immune
mechanisms are likely important in the pathogenesis of
AMR and CAV. Non-HLA antibodies to collagen-V and
Ka1-tubulin have also been shown to correlate with the
developmentofDSAinhearttransplantrecipientsdiagnosed
with AMR [19]. Non-HLA antibodies likely damage the
allograft through both complement dependent and indepen-
dent pathways. Antibodies to MICA, however, have not been
showntocorrelatewithrejectionepisodes,survival,andCAV
following heart transplantation [20]. In this study, DSA was
conﬁrmed to be an independent risk factor for poor allograft
survival, but MICA antibodies did not aﬀect transplant
outcomes. The precise role of non-HLA antibodies in AMR
remains unclear and more importantly, whether routine
detection of these antibodies will impact on the diagnosis of
AMR is unknown.
3.Diagnosis
The diagnostic criteria for AMR have undergone signiﬁcant
revision. A key diﬀerence between the 2005 and 2011
ISHLT guidelines is the proposed shift from a clinical to
pathologic diagnosis. The 2005 guidelines recommended
diagnosis of AMR based on interpretation of pathologic
changes in conjunction with cardiac allograft dysfunction
and/or hemodynamic compromise and the presence of DSA
[6].AMRhassincebeenrecognizedtoexistalongaspectrum
from an asymptomatic phase with occurrence of DSA in
isolation to a symptomatic phase with allograft dysfunction
and hemodynamic compromise. This is a clinically useful
distinction as asymptomatic AMR has been shown to be
associated with poorer outcomes [2, 21]. Furthermore, a
universally accepted deﬁnition for allograft dysfunction does
not exist. Allograft dysfunction has been variably described
as symptomatic heart failure, left ventricular dysfunction as
well as hemodynamic evidence of increased cardiac ﬁlling
pressures and low cardiac output. Proposed criteria deﬁning
allograft dysfunction is shown in Table 1.I m p o r t a n t l y ,i t
should be recognized that clinical and hemodynamic param-
eters,eveninthepresenceofpreservedejectionfraction,may
also indicate allograft dysfunction.
Screening for DSA is an important component of im-
mune surveillance following heart transplantation. Screen-
ing is typically performed with solid phase assays using
recombinant HLA-protein-coated beads [22]. Detection of
DSA does not, however, conﬁrm the diagnosis of AMR.Journal of Transplantation 3
Circulating DSA may not inﬂict allograft injury, existing as
part of a immunologic process known as accommodation.
Accommodation refers to normal allograft function and the
absence of antibody-mediated injury despite the presence
of circulating DSA [23]. Postulated mechanisms for ac-
commodation include loss of antigens on the allograft,
upregulationofcytoprotectivemolecules,andclassswitching
of antibodies to noncomplement activating subclasses [23].
Another caveat in screening for DSA is that AMR is not
excluded by the absence of DSA. In biopsy-proven AMR,
DSA may be entirely bound to the allograft and undetectable
in the circulation. As an example, Bocrie et al., demonstrated
the presence of DSA in eluates from 58.3% of renal allografts
with chronic allograft nephropathy but only detectable in
the peripheral blood in 16.6% of cases [24]. Thus, current
2011 ISHLT guidelines focus on pathologic features of AMR
with demonstration of DSA supportive, but not essential for
diagnosis.
3.1. Histopathology. Histologic features of AMR as deﬁned
by the 2005 ISHLT guidelines include “myocardial injury
with endothelial cell swelling and intravascular macrophage
accumulation.” Additional features include “interstitial
edema and hemorrhage” as well as “intravascular thrombi
and myocyte necrosis” [6]. Importantly, many of these
f e a t u r e sm a yo n l yb eo b s e r v e di ns e v e r ec a s e so fA M Rw i t h
early or less severe cases displaying fewer histologic changes.
Several groups have conﬁrmed poor accuracy of isolated
histologic features to diagnose AMR. In a study of 3,170
biopsies, Hammond et al. demonstrated a low sensitivity of
63% for endothelial swelling and 30% for vascular adherence
of macrophages in the diagnosis of AMR [25]. In a more
recent study, morphometric features of early or subclinical
AMR lacked suﬃcient sensitivity when compared to more
sensitive detection stains such as C4d [26].
3.2. Immunopathology. Detection of AMR may be improved
by immunopathologic examination of endomyocardial bi-
opsy specimens. The 2005 ISHLT guidelines recommended
immunoﬂuorescence or immunohistochemical staining on
frozen and paraﬃn sections, respectively. Immunoﬂuo-
rescence stains detect immunoglobulin and complement
(C3d, C4d, and/or C1q) deposition within capillaries, while
immunohistochemistry stains detect capillary CD68 positive
macrophages and C4d deposition [6]. The 2011 ISHLT
guidelines expanded the recommended immunopathologic
panel to include HLA for assessment of capillary integrity,
immunoglobulins and ﬁbrin by immunoﬂuorescence and
C3d, vascular markers CD34 and CD31, as well as CD3 and
CD20 by paraﬃn immunohistochemistry [7].
C4d deposition has been evaluated in multiple studies
as a potential marker for AMR. Gupta et al. evaluated the
routine use of C4d immunoﬂuorescence on endomyocardial
biopsiesaftertransplantandfoundthatpositiveC4dstaining
correlated with a positive retrospective crossmatch and
the presence of DSA [27]. Rodriguez et al. demonstrated
that C4d coupled with C3d immunoﬂuorescence correlated
with a clinical diagnosis of AMR [28]. Interestingly, they
found that Immunoglobulin and C1q staining provided no
incremental beneﬁt for AMR diagnosis. Immunoglobulins
were frequently detected and associated with a staining
patternthatdidnotcorrelatewiththepatternofcomplement
deposition. The use of combined C3d and C4d immunoﬂu-
orescence staining to detect AMR was also evaluated by
Tan et al. who found that this combination could reliably
detect AMR deﬁned by the presence of DSA and graft
dysfunction [29]. Future studies are needed to conﬁrm a role
for C3d staining in addition to C4d in detecting AMR and to
determine if immunoﬂuorescence and paraﬃni m m u n o h i s -
tochemistry detection techniques for C3d are equivalent.
A potentially useful marker of AMR is CD68, a cell
surface antigen present on macrophages. Rodriguez et al.
showed that patients with graft dysfunction likely related to
AMR had positive staining for intravascular macrophages
while patients with preserved graft function did not display
CD68 staining [28].Severalstudieshavedemonstratedacor-
relation between the presence of intravascular macrophages
and AMR [30, 31]. CD68 positivity may identify a more
severe form of AMR associated with allograft dysfunction,
and therefore early AMR may not be detected with this stain.
Further work is necessary to determine antigen staining
combinations sensitive to and speciﬁc for AMR that can also
detect early damage due to antibody deposition. Figure 1
shows examples of histopathologic and immunopathologic
biopsy ﬁndings of AMR in heart transplantation.
3.3. ISHLT Guidelines. The ISHLT recently proposed a new
AMR grading scheme that is focussed on a shift towards
a pathologic diagnosis [8]. The proposed AMR grading
scheme incorporates an AMR severity scale from pAMR 0
to pAMR 3 (“p” reﬂecting a pathologic-based diagnosis).
A biopsy with pAMR 0 has neither histopathologic nor
immunopathologic features of AMR. A biopsy with pAMR
1 has either histopathologic or immunopathologic features.
A biopsy with pAMR 2 has both histopathologic and
immunopathologic features. Finally, a biopsy with pAMR 3
has severe pathologic features of AMR such as interstitial
hemorrhage and signiﬁcant edema. Similar to the current
grading scheme for cell-mediated rejection, associated clin-
ical ﬁndings such as “hemodynamic compromise” may assist
but are not required for diagnosis.
A proposed timeline for AMR screening is also proposed
in the new ISHLT guidelines [7]. The guidelines recommend
that all biopsies be routinely evaluated for histopathologic
evidence of AMR. Immunopathologic testing on biopsies in
the ﬁrst year is recommended at 2 weeks and at 1, 3, 6,
and 12 months after transplant. Interval immunopathologic
testing is recommended if there is occurrence of histologic,
serologic, or clinical suspicion of AMR. The guidelines also
recommend that following a positive biopsy result, repeat
testing should be performed on subsequent biopsies until a
negative result is obtained. DSA is an important monitoring
toolforAMR,andtheISHLTrecommendstestingwitheither
solid phase- or cell-based assays at 2 weeks and at 1, 3, 6, and
12 months after heart transplant and annually thereafter, in
the absence of clinical suspicion.4 Journal of Transplantation
(a) (b)
(c)
Figure 1: Histopathologic and immunopathologic biopsy features of AMR. (a) A biopsy sample stained with hematoxylin and eosin
shows evidence of endothelial cell swelling (arrow). (b) An immunoperoxidase stain shows diﬀuse C4d deposition in capillaries. (c) An
immunoperoxidase stain conﬁrms the presence of intravascular macrophages with positive staining for CD68.
3.4. Future Directions for Diagnosis. There has been growing
interest in the use of microarray technology to monitor gene
expression and diagnose AMR. Microarrays were used to
study endothelial-associated gene transcripts (ENDATs) in
kidney allograft biopsies [32, 33]. In comparison to C4d,
ENDATexpressionshowedimprovedaccuracyforpredicting
graft loss in DSA positive patients: 77% sensitivity for
ENDAT versus 31% for C4d. The authors suggest that non-
complement ﬁxing DSA may potentially be as damaging
to endothelial and graft function as complement ﬁxing
DSA. The combination of DSA and ENDAT expression
thus identiﬁes a population of patients with active antibody
mediated damage to endothelial cells and a poor prognosis.
This type of molecular screening tool may prove useful in
detecting both early stages of AMR and also AMR due to
non-complement ﬁxing DSA. At present, it is unclear if
similar measurements can be made in cardiac biopsies and
if they will provide additional predictive value in diagnosing
AMR compared to stains such as C4d.
4. Management
The development of evidence-based guidelines for the
management of AMR in heart transplantation is greatly
needed.Persistingcontroversyoverthediagnosticcriteriafor
AMR, continued development of diagnostic techniques and
a paucity of robust data to substantiate traditional therapies
represent important challenges. At present, the management
of AMR is nonstandardized, and optimal surveillance,
treatment, and timing of intervention are undeﬁned. AMR is
diﬃcult to treat, and therapy remains empiric with support-
ing evidence limited to small, nonrandomized studies with
short followup. Furthermore, although it is widely accepted
that AMR associated with allograft dysfunction should be
aggressively treated, the management of asymptomatic AMR
is less clear. While close surveillance is advocated for this
group of patients, the ideal frequency and mode of assess-
mentincludingevaluationofallograftfunction,performance
of endomyocardial biopsies, and HLA antibody screening
are unknown. Additionally, although studies suggest thatJournal of Transplantation 5
∗Endomyocardial biopsy
Histopathology
Capillary injury: endothelial swelling
Intravascular macrophages; neutrophils
Interstitial edema
Interstitial hemorrhage
No AMR
pAMR 0
AMR
pAMR 1–3
No Yes
Allograft dysfunction
Allograft 
Immunopathology (IF; IH)
AMR
Asymptomatic
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Symptomatic
dysfunction
Complement activation: C4d; C3d
Macrophage: CD68
Immunoglobulins: IgG; IgM; IgA
Vascular: CD31; CD34
T cell:CD3
Treatment
T-cell suppression: steroids; cytolytics; CNI;MMF; PSI
Antibody removal/blockade: plasmapheresis; IVIG
B-cell depletion: rituximab
Plasma cell depletion: bortezomib
Complement inhibition: eculizumab
‡Increased
surveillance
†Routine
surveillance
Figure 2: Proposed management algorithm for AMR in heart transplantation. AMR: antibody-mediated rejection, CNI: calcineurin
inhibitors, DSA: donor speciﬁc antibodies, IF: immunoﬂuorescence, IH: immunohistochemistry, IVIG: intravenous immunoglobulin,
MMF: mycophenolate mofetil, pAMR: ISHLT pathologic AMR grade 0–3, and PSI: proliferation signal inhibitor. ∗Endomyocardial biopsy
frequency as per institution protocol. †DSA monitoring at week 2, months 1, 3, 6, and 12 in ﬁrst year after transplant and annually thereafter.
‡Assessment of allograft function every month and DSA every 3 months until two negative or unchanged results.
asymptomatic AMR is associated with reduced patient sur-
vival, and an increased risk for development of CAV, im-
plementation of surveillance and treatment has not been
proven to improve outcomes [2, 21].
A proposed management algorithm for AMR is sum-
marized in Figure 2. Incorporating the recent 2011 ISHLT
guidelines, AMR is diagnosed by identifying speciﬁc histo-
pathologic and/or immunopathologic features on endomy-
ocardialbiopsy.Treatmentisrecommendedforsymptomatic
AMR, although less certain for asymptomatic AMR. Allo-
graft dysfunction, based on clinical, hemodynamic and
imaging parameters diﬀerentiates symptomatic from asymp-
tomatic AMR (Table 1). Routine posttransplant surveil-
lance for AMR should include pathologic evaluation on
endomyocardialbiopsy,assessmentofallograftfunction,and
monitoring for DSA.In individuals with pathologic evidence
ofAMR,increasedfrequencyofsurveillanceisrecommended
with assessment of allograft function every month and
DSA monitoring every three months until two negative or
unchanged results (Figures 2 and 3).
A potential DSA monitoring algorithm is shown in
Figure 3. Individuals with DSA should be evaluated for
AMR with endomyocardial biopsy and allograft function
assessment. De novo DSA, especially those that persist, is an
independent predictor of poor survival after transplant [34].
Thus, although not proven to improve outcomes, treatment
may be considered in patients with asymptomatic AMR who
develop DSA. The presence of DSA associated with new
and otherwise unexplained allograft dysfunction raises the
suspicion of AMR and consideration for treatment. As DSA
mayexistwithoutcausingallograftinjury(accommodation),
their detection in the circulation in isolation without allo-
graft dysfunction or biopsy features of AMR may not require
treatment. The presence of DSA should prompt increased
AMR surveillance. Additionally, increased AMR surveillance
is also recommended in individuals who develop de novo6 Journal of Transplantation
DSA
No Yes
Yes No
†Routine
surveillance
∗Increased
surveillance
∗Increased
surveillance Treatment
Positive Negative
Endomyocardial
biopsy
Allograft
dysfunction
Figure 3: Proposed DSA treatment algorithm. AMR: antibody-mediated rejection, DSA: donor-speciﬁc antibodies. ∗Assessment of allograft
function every month and DSA every 3 months until two negative or unchanged results. †DSA monitoring at week 2, months 1, 3, 6, and 12
in ﬁrst year after transplant and annually thereafter.
non-HLA antibodies due to the potential risk of heightened
humoral activation.
5. Treatment
Altered humoral immunity with plasma cell production of
antibodies directed against donor antigens on the allograft is
primarily responsible for myocardial injury in AMR. Plasma
cells are generated by T-lymphocyte-dependent activation
andgenerationofmemoryB-lymphocytes.Treatmentstrate-
gies for AMR are directed at inhibiting the humoral response
at various levels by targeting (1) removal and blockade of
circulating antibodies, (2) depletion of B-lymphocytes, (3)
depletion of plasma cells, (4) suppression of T-lymphocyte
dependent antibody responses, and (5) inhibition of the
complement cascade. While several agents have been used
successfully and others show promise, AMR remains diﬃcult
to treat and is often refractory to therapy.
5.1. T-Lymphocyte Suppression. B-lymphocyte responses, in-
clud-ingB-lymphocyteactivation,thegenerationofmemory
B-lymphocytes, and high-aﬃnity antibodies are dependent
on T-lymphocytes. Suppression of T-lymphocytes, therefore,
indirectly inhibits B-lymphocytes. Cytolytic antibodies (thy-
moglobulin; OKT3), corticosteroids, calcineurin inhibitors
(cyclosporine; tacrolimus), mycophenolate mofetil, and pro-
liferation signal inhibitors (sirolimus; everolimus) inhibit
T-cell proliferation and/or activation through a variety of
mechanisms and may be used to treat AMR. Many of these
drugsalsoexhibitdirecteﬀectsonB-lymphocytes.Forexam-
ple, thymoglobulin is a polyclonal antibody containing mul-
tiple anti-T-lymphocyte antibodies that target classes I and
II,HLAmolecules,associatedligands(CD3,CD4,andCD8),
costimulatory molecules, cell adhesion molecules as well
as surface molecules expressed on B-lymphocytes (CD20)
and plasma cells (CD38 and CD138) [35]. Calcineurin
inhibitors have antiproliferative and proapoptotic eﬀects on
activatedB-lymphocytes.Mycophenolatemofetilmayleadto
hypogammaglobulinemia, and there is in vitro evidence that
it plays a direct role in inhibiting B-lymphocytes [36, 37].
The eﬃcacy of single or combination immunosuppression
therapy for the prevention and/or treatment of AMR has
not been evaluated. Baseline immunosuppression is usually
augmented after AMR.
5.2. Plasmapheresis. Plasmapheresis removes circulating
plasma antibodies by extracorporeal separation of plasma
from cellular blood components using either centrifuga-
tion or membrane ﬁltration. As antibody production is
unaﬀected, antibody levels may increase after discontinu-
ation of plasmapheresis. Potential adverse eﬀects include
complications related to vascular access, hypotension due
intravascularvolumecontraction,bleedingfromdepletionof
clotting factors as well as allergic reactions and blood-borne
infectionfromplasmarepletionwithreplacementﬂuidssuch
as albumin and fresh frozen plasma.
In 2001, Grauhan et al. published the ﬁrst clinical case
series of plasmapheresis for the treatment of AMR after
heart transplantation [38]. Between 1986 and 1999, 18
episodesofAMRwithassociatedhemodynamiccompromise
involving 13 patients were identiﬁed. All patients received
treatment with corticosteroids and cytolytic antibodies with
the addition of plasmapheresis in six patients. All six patients
treated with plasmapheresis survived, while only two of
seven patients in the nonplasmapheresis group survived. The
authors concluded that a randomized controlled study was
justiﬁed; however, only small case series (n< 15) followed.
Although these small studies have consistently demonstrated
that plasmapheresis is an eﬀective treatment for AMR,
variation in protocols with diﬀering duration and frequency
of treatment and adjunctive treatment confounds interpre-
tation. Similarly, an ideal plasmapheresis treatment regimenJournal of Transplantation 7
has not been established with the number of treatments in
studies varying from days to weeks.
5.3. Intravenous Immunoglobulin. Intravenous immuno-
globulin (IVIG) is comprised of 90% IgG, extracted from
pooled plasma from between 50,000 and 100,000 blood
donors [39]. A number of immunomodulatory eﬀects have
been described for IVIG including blockade of Fc recep-
tors, complement inhibition, and downregulation of B-
lymphocyte receptors [39]. IVIG is used as standard therapy
for primary immune deﬁciencies, autoimmune and inﬂam-
matory disorders. Various IVIG preparations are available,
diﬀering in IgG concentration, osmolarity, and sodium
and sugar content. IVIG is generally well tolerated with a
<5% incidence of adverse reactions including mild infusion-
related eﬀects (usually ﬁrst dose) that generally improve
with temporary cessation or reduction in infusion rate,
anaphylactic reactions associated with IgA sensitization in
patients with IgA deﬁciency, thrombosis, and volume over-
load. The latter is due to an average volume requirement of
1 to 1.5 L (treatment dose 1-2g/kg) and sodium load for
drug administration, and poses diﬃculties for its application
in patients with cardiac AMR with concurrent allograft
dysfunction and heart failure.
Experience with IVIG in transplantation is largely de-
rived from renal transplantation. In this patient population,
IVIG has mostly been evaluated for desensitization and
shown to reduce PRA and increase conversion to a negative
complement dependent cytotoxic crossmatch [40]. Recently,
Montgomery et al. reported superior patient survival for
sensitized individuals undergoing desensitization with IVIG
and plasmapheresis prior to transplant in comparison to
patients undergoing an HLA-matched transplant [41]. IVIG
has also been used successfully to treat AMR after renal
transplant, usually in combination with plasmapheresis and
rituximab [42–44]. Data from large case series are, however,
notavailable,andIVIGhasnotbeensystematicallyevaluated
for the treatment of AMR after heart transplant. Jordan et al.
were the ﬁrst to describe the successful treatment of AMR
after heart transplant with IVIG. Three cardiac and seven
renal transplant patients with severe AMR were treated with
IVIG [45]. All cardiac patients had reversal of AMR and
survived to six months. All seven renal patients recovered
with no recurrent events. All ten patients demonstrated a
rapid reduction in DSA.
5.4. Rituximab. Rituximab is a chimeric monoclonal IgG
antibody, comprised of human constant regions and
mouse variable regions directed against the CD20 pan-B
lymphocyte surface molecule. Rituximab depletes B-lym-
phocytes by antibody-dependent cell-mediated cytotoxic-
ity, complement-dependent cytotoxicity, and induction of
apoptosis through CD20 cellular crosslinking and caspase
activation [46]. Rituximab was originally approved for
the treatment of B-cell lymphoma and is now also used
for a number of autoimmune diseases including immune
thrombocytopenic purpura and myasthenia gravis.
The eﬃcacy of Rituximab for AMR treatment after heart
transplant has only been examined in case reports and one
small case series (n = 8) [47]. The majority found a beneﬁt
by demonstrating improved allograft function. Most cen-
tres, however, administered rituximab in combination with
other treatments, preventing sole evaluation of rituximab.
Although the ideal dosing for rituximab is unknown, a
commonly used regimen in these and hematologic studies
is 375mg/m2/ w e e kf o ru pt o4w e e k s .P h a r m a c o d y n a m i c
studies in patients with lymphoma have shown maximal B-
lymphocyte depleting eﬀects at three to four months with
low or undetectable numbers in the peripheral blood for
up to six months and full recovery within 12 months [48].
Interestingly, it has been demonstrated in patients with
end-stage renal disease that a similar reduction in PRA,
and B-lymphocyte depletion may be achieved using low
(50mg/m2) or high doses (150 and 375mg/m2) of rit-
uximab [49]. Furthermore, Fc gamma receptor polymor-
phisms aﬀecting antibody-dependent cell-mediated cytotox-
icity results in variation in rituximab induced B-lymphocyte
depletion among individuals, producing further complexity
in determining an ideal treatment dosing regimen [50, 51].
The safety and tolerability of rituximab is well estab-
lished in the context of hematologic malignancies. Mild-to-
moderate ﬁrst dose infusion-related reaction with fever and
hives account for the majority of adverse eﬀects. Concerns
have, however, been raised over an increased risk of serious
infections with rituximab therapy after transplantation. In a
study of 22 renal transplant recipients, rituximab was shown
to be eﬀective in treating AMR but associated with a high
incidence of infection [52]. Eighty-six percent of patients
experienced serious infection including three cases of septic
shock. It is probable that cumulative immunosuppression
was intense and contributed to the development of infec-
tion as rituximab was administered in combination with
six sessions of plasmapheresis, pulse steroids, tacrolimus,
mycophenolate mofetil as well as cytolytic antibodies in a
proportion of patients.
5.5. Bortezomib. Proteasomes are responsible for the pro-
cessinganddegradationofubiquitin-labeledproteins.Borte-
zomib is a selective 26S proteasome inhibitor depleting
plasma cells and antibody production by inducing apoptosis
via cell cycle arrest as well as inducing the unfolded protein
response due to increased endoplasmic reticulum stress from
accumulation of misfolded proteins [53, 54]. Additional
immunomodulatory eﬀects of bortezomib include gene
transcriptional activator nuclear factor kappa B inhibition
and inhibition of antigen processing by preventing peptide
generation and MHC class I expression [53, 54].
Bortezomib is currently approved for the treatment of
multiple myeloma. Small studies in renal transplant patients
have shown that bortezomib eﬀectively decreases HLA anti-
bodies in patients with stable renal function and is eﬀective
in treating refractory AMR [55–59]. Woodle et al. recently
presented results from the largest multicentre study of 107
cases of AMR in 91 solid organ transplant recipients [60].
The patient population comprised predominantly of kidney
transplant recipients (n = 81), but also included ﬁve
heart transplant recipients. Bortezomib was administered
in four doses, each preceded by plasmapheresis, and all8 Journal of Transplantation
patients also received a single dose of rituximab. Over
an average 9 month followup, 58% of patients showed
histologic improvement, with 81% and 96% graft and
patient survival, respectively. Additionally, there was a >50%
reduction in DSA in 40% of patients at 14 days after treat-
ment. An 11.2% incidence of opportunistic infection was
reported. Studies in transplantation and multiple myeloma
series have reported high tolerability of Bortezomib with
common adverse eﬀects including fatigue, gastrointestinal
toxicity, thrombocytopenia, neutropenia, and peripheral
neuropathy.
5.6. Eculizumab. Eculizumab is a humanized monoclonal
antibody directed against C5, thereby preventing comple-
ment activation by inhibiting cleavage of C5 to C5a and C5b,
andformationofthemembraneattackcomplex.Eculizumab
iscurrentlyapprovedintheUnitedStatesforthetreatmentof
paroxysmalnocturnalhemoglobinuria.Experimentalstudies
in sensitized mice have shown that eculizumab as part
of a multi-immunosuppressive regimen prevents allograft
rejection and improves allograft survival [61]. At present,
clinical studies of eculizumab in AMR are observational and
preliminary. Locke et al. reported the successful treatment
of a renal transplant recipient with refractory AMR using
eculizumab [62]. In another study of highly sensitized renal
transplant patients with DSA, a signiﬁcant reduction in
incidence of early AMR at <3 months was demonstrated for
eculizumab(6.25%incidenceofAMRforeculizumabtreated
group compared to 40% for the historical control group)
[63].
6. Conclusion
The diagnosis and management of AMR in heart transplan-
tation has evolved signiﬁcantly over the last decade. Cur-
rent international multidisciplinary consensus recommend
a pathologic-based diagnosis, combining speciﬁc histologic
and immunopathologic features on endomyocardial biopsy
and utilizing accompanying allograft dysfunction and/or
circulating DSA as additional supporting evidence. AMR as
a disease entity will continue to evolve and become bet-
ter deﬁned with advances in diagnostic techniques and im-
proved understanding of key pathogenic molecular and
immunologic mechanisms. Current available therapeutic
options modify the humoral immune response by targeting
the removal and blockade of antibodies, and the depletion
of T- and B-lymphocytes. Emerging therapies showing
promise include agents that directly deplete plasma cells
and antibody production, such as bortezomib, as well as
complement inhibiting agents such as eculizumab. The
scarcity of heart transplantation as a clinical resource and
current poor patient and allograft outcomes associated
with AMR provide signiﬁcant impetus for the development
of eﬀective treatment strategies. It is anticipated that the
2011 ISHLT consensus guidelines on AMR diagnosis and
management will further facilitate the goal of developing a
standardized evidence based management approach to AMR
in heart transplantation.
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